The response rate is higher. 4/4 100% of the patients who received 400mg in phase 1b dose escalation trial received a PR….
2 at 40% shrinkage 1 at 60% shrinkage 1 at 80% shrinkage of tumour.
Small n, but if this continues over the 50 patients its a company maker
- Forums
- ASX - By Stock
- ATX
- Ann: Additional Patient Response in Pancreatic Cancer Trial
ATX
amplia therapeutics limited
Add to My Watchlist
0.00%
!
28.5¢

Ann: Additional Patient Response in Pancreatic Cancer Trial, page-9
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
28.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $110.7M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 32427 | 31.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
26.0¢ | 4482 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 32427 | 0.310 |
1 | 995 | 0.295 |
4 | 15648 | 0.290 |
9 | 69447 | 0.285 |
15 | 375879 | 0.280 |
Price($) | Vol. | No. |
---|---|---|
0.270 | 21800 | 2 |
0.280 | 40000 | 2 |
0.285 | 54979 | 3 |
0.290 | 27857 | 2 |
0.295 | 190415 | 3 |
Last trade - 09.51am 16/07/2025 (20 minute delay) ? |
Featured News
ATX (ASX) Chart |
The Watchlist
HAR
HARANGA RESOURCES LIMITED.
Peter Batten, MD
Peter Batten
MD
Previous Video
Next Video
SPONSORED BY The Market Online